Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 11, 2021

Ampio gets approval to begin Phase I trial for long-haul Covid-19

Ampio Pharmaceuticals has secured Investigational Review Board (IRB) approval for its Phase I trial against long-haul Covid-19.

Ampio Pharmaceuticals has secured Investigational Review Board (IRB) approval for its Phase I trial against long-haul Covid-19.

Named AP-018, the trial will assess the use of inhaled Ampion to treat patients with prolonged respiratory Covid-19 symptoms or Post-Acute Sequelae of SARS-CoV-2. Enrolment is set to begin soon.

It will study the therapeutic’s safety and efficacy in 30 adults with a confirmed Covid-19 diagnosis and a minimum of two respiratory symptoms related to the disease.

Participants will receive a nebuliser for use at home for five days and will be followed for 60 days after treatment.

The trial’s primary endpoint is the incidence and severity of adverse events (AEs) and serious AEs from baseline to days 28 and 60.

Exploratory efficacy endpoints will compare inhaled Ampion to placebo on the clinical outcomes in individuals with long-haul respiratory Covid-19 complications.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Ampio Pharmaceuticals president and CEO Michael Macaluso said: “A significant percentage of patients who have contracted Covid-19 over the past year, even those with mild or asymptomatic cases, continue to suffer debilitating effects long after there is no detectable virus in their system.

“These symptoms stem from the out-of-control inflammatory immune response the virus triggers, something Ampion may be able to address.”

Last month, all participants in the company’s Phase I AP-014 trial of inhaled Ampion completed treatment against Covid-19, including a follow-up at day 28 following treatment.

The primary endpoint of safety and tolerability was met. Final results revealed that Ampion led to a 78% decrease in all-cause mortality for Covid-19 respiratory distress compared to the standard of care (SOC).

Mortality was 5% in the Ampion arm versus 24% in the SOC group.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU